Cat Feline Infectious Peritonitis: Welfare Through a Once-Fatal Disease

Feline infectious peritonitis (FIP) was until recently a universally fatal disease causing significant suffering. The development of effective antiviral treatments has transformed it from a welfare crisis to a manageable condition — one of veterinary medicine's greatest recent advances.

Key Facts

FIP is caused by a mutated form of feline coronavirus (FCoV) that triggers an abnormal immune response leading to inflammatory disease; wet FIP causes fluid accumulation, dry FIP causes granulomatous inflammation in organs
Until 2019, FIP was universally fatal and considered incurable; diagnosis was itself effectively a death sentence, leading most owners to pursue euthanasia
GS-441524 (a nucleoside analogue antiviral) and its prodrug GC376 were demonstrated in landmark studies by Pedersen and colleagues to achieve clinical remission in >80% of treated FIP cats
Treatment requires 12 weeks of daily medication and is expensive — costs range from £1,000–£5,000+ depending on cat size, disease type, and medication source
Mutian, GS-441524, and related compounds were initially only available through Chinese online suppliers outside regulatory approval; the EU-approved drug Vitafel received approval in 2021 and Xraphcobus (GS-441524 prodrug) followed
Shelter cats and cats in multi-cat households are at elevated FCoV exposure risk; good biosanitation (litter box hygiene, density management) reduces FCoV spread and therefore FIP mutation risk
Neurological FIP, which affects the brain and spinal cord, can also be treated successfully with GS-441524 though typically requires higher doses and longer treatment duration

Welfare Considerations

The welfare story of FIP is one of veterinary medicine's most dramatic recent transformations. Before 2019, cats diagnosed with FIP faced certain death — the progressive systemic inflammation of wet FIP caused increasing abdominal distension, weakness, and debilitation before death or euthanasia. Dry FIP caused progressive organ failure with neurological signs in some cases. The subjective suffering of cats with advanced untreated FIP was significant and prolonged. The development of GS-441524-based treatments has changed this completely: cats that would previously have been euthanised within weeks of diagnosis now achieve sustained remission, resume normal lives, and in the majority of cases remain in remission permanently. The principal remaining welfare challenge is access: treatment cost means that some owners cannot afford treatment, and geographic variation in drug regulatory approval affects availability. Ensuring that this life-saving treatment reaches all cats who need it — regardless of owner financial circumstances — is the outstanding welfare equity challenge in FIP management.

What You Can Do

If your cat is diagnosed with FIP, seek immediate consultation with a specialist familiar with GS-441524 treatment — this disease is now treatable
Contact the FIP Warriors support group and FIP Warriors 5.0 for guidance on accessing treatment and cost management options
Support veterinary school scholarship funds and charitable organisations that help fund FIP treatment for owners who cannot afford commercial pricing
Advocate for prompt regulatory approval of GS-441524 and related compounds in all countries where cats with FIP currently have no access to approved treatment
Maintain good litter box hygiene in multi-cat households and avoid overcrowding to reduce FCoV transmission risk